Protective effects of rosiglitazone on myocardial ischemia in diabetic mice

Xiang Xuejun,Zhang Tingting,Hong Hao
DOI: https://doi.org/10.3969/j.issn.1000-1492.2011.10.013
2011-01-01
Abstract:Objective To investigate the protective effect of PPARγ agonist rosiglitazone on acute myocardial ischemia injury in diabetic mice.Methods Caudal vein injection of streptozotocin(STZ)(150 mg/kg)was used to induce type 1 diabetes model(DM)in mice,then the diabetic mice were randomly divided into four groups,the DM group,diabetic-myocardial ischemia(DMI) group,mice in DMI group were treated with high dose 3.2 mg/(kg·d)and low dose 1.6 mg/(kg·d) of rosiglitazone,accompanying with age-matched control mice.Acute myocardial ischemia injury was induced with subcutaneous injection of isoprenaline(ISO)(20 mg/kg) at the back for two days after administration of the diabetic mice with rosiglitazone for one week.The electrocardiograms were analyzed,the activities of LDH and CK in serum as well as the SOD activity in the myocardial tissue were assayed.Pathological slides of myocardium from the groups were also examined,and the fasting serum glucose(FSG) and insulin were determined.Results Compared with the DMI control mice,the mice administrated with high dose and low dose of rosiglitazone showed significant lower ECG-ST segments,and significant amelioration of the tissue degeneration of myocardial tissue observed by light microscope.In addition,the levels of serum CK and LDH in the DMI mice pretreated with rosiglitazone were significantly decreased,and the activities of myocardial SOD were significantly elevated.However,rosiglitazone had no significant influence on the blood glucose and serum insulin levels in the DMI mice.Conclusion Rosiglitazone significantly improve the myocardial ischemia injury in diabetic mice,which is involved in the elevation of the SOD activity in the myocardial tissue.
What problem does this paper attempt to address?